Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.40 |
| ▸ | LPL | P06858 | 13/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4578027 | 0.86 | AAK1 (0.39) | AAK1LPLLIPGCA1CA2 | |
| SCHEMBL2497084 | 0.82 | AAK1 (0.41) | AAK1LPLLIPGCA1CA2 | |
| SCHEMBL9910113 | 0.82 | PDE2A (0.44) | AAK1LPLLIPGCA1CA2 | |
| SCHEMBL2699826 | 0.82 | PDE2A (0.44) | AAK1LPLLIPGCA1CA2 | |
| SCHEMBL3025664 | 0.82 | LMNA (0.50) | AAK1LPLLIPGCA1CA2 | |
| SCHEMBL2411421 | 0.80 | LPL (0.44) | AAK1LPLLIPGCA1CA2 | |
| SCHEMBL1678963 | 0.77 | AAK1 (0.43) | AAK1LPLLIPGCA1CA2 | |
| SCHEMBL16317403 | 0.77 | AAK1 (0.39) | AAK1LPLLIPGCA1CA2 | |
| SCHEMBL419648 | 0.76 | LPL (0.48) | AAK1LPLLIPGCA1CA2 | |
| SCHEMBL13896741 | 0.75 | AAK1 (0.38) | AAK1LPLLIPGCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3243515-B1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2019-10-16 | — | — | EP | disclosed |
| EP-3169684-B1 | COMBINATION OF KMO INHIBITOR 6-(3-CHLORO-4-CYCLOPROPOXYPHENYL)PYRIMIDINE-4-CARBOXYLIC ACID WITH ANTIVIRAL AGENT FOR TREATING HIV RELATED NEUROLOGICAL DISORDERS | CHDI FOUNDATION INC (US) | 2019-06-26 | — | — | EP | disclosed |
| US-9981918-B2 | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981918-B2 | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3243515-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI Foundation, Inc. (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170209440-A1 | METHODS AND COMPOSITIONS FOR TREATING HIV-RELATED DISORDERS | CHDI FOUNDATION, INC. | 2017-07-27 | — | — | US | disclosed |
| US-20170209440-A1 | METHODS AND COMPOSITIONS FOR TREATING HIV-RELATED DISORDERS | CHDI FOUNDATION, INC. | 2017-07-27 | — | — | US | disclosed |
| EP-2750677-B1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20160251318-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2016-09-01 | — | — | US | disclosed |
| US-20160251318-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2016-09-01 | — | — | US | disclosed |
| WO-2016011316-A1 | METHODS AND COMPOSITIONS FOR TREATING HIV-RELATED DISORDERS | CHDI FOUNDATION, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| WO-2013033085-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | COURTNEY STEPHEN MARTIN (GB) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251318-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KMO, KYNU, HAAO | AAK1 1307/4885LPL 1239/4885LIPG 1707/4885 |
| US-20170209440-A1 | METHODS AND COMPOSITIONS FOR TREATING HIV-RELATED DISORDERS | KMO, KYNU, PNPO | AAK1 412/4885LPL 2726/4885LIPG 2302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.